SCOPUS 정보 검색 플랫폼

The Lancet Infectious Diseases

Volumn 13, Issue 3, 2013, Pages 195-

Cross protection against HPV might prevent type replacement

(3) Verdenius, Inge a Groner, Jennifer A b Harper, Diane M b

a RADBOUD UNIVERSITY MEDICAL CENTER (Netherlands)

b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER INCIDENCE; CONDYLOMA ACUMINATUM; CROSS PROTECTION; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LETTER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; CROSS PROTECTION; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; YOUNG ADULT;

EID: 84874285966 PISSN: 14733099 EISSN: 14744457 Source Type: Journal
DOI: 10.1016/S1473-3099(13)70024-0 Document Type: Letter

Times cited : (8)

References (5)

1
- 84874286717
- Prophylactic HPV vaccines and prevention of cervical intraepithelial neoplasia
- Heitmann ER, Harper DM Prophylactic HPV vaccines and prevention of cervical intraepithelial neoplasia. Curr Obstet Gynecol Rep 2012, 1:95-105.
- (2012) Curr Obstet Gynecol Rep , vol.1 , pp. 95-105
- Heitmann, E.R.¹ Harper, D.M.²

2
- 23244438005
- The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
- Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
- (2005) J Natl Cancer Inst , vol.97 , pp. 1072-1079
- Khan, M.J.¹ Castle, P.E.² Lorincz, A.T.³

3
- 84866628242
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
- Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789.
- (2012) Lancet Infect Dis , vol.12 , pp. 781-789
- Malagón, T.¹ Drolet, M.² Boily, M.C.³

4
- 84855309413
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- for the HPV PATRICIA Study Group
- Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110. for the HPV PATRICIA Study Group.
- (2012) Lancet Oncol , vol.13 , pp. 100-110
- Wheeler, C.M.¹ Castellsagué, X.² Garland, S.M.³

5
- 84864528970
- Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction
- Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130:249-256.
- (2012) Pediatrics , vol.130 , pp. 249-256
- Kahn, J.A.¹ Brown, D.R.² Ding, L.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.